{ "ok": true, "cik": "1505497", "ticker": "BRTX", "name": "BIORESTORATIVE THERAPIES, INC.", "filings": [ { "form": "8-K", "filed": "2026-09-11", "items": [ "5.02 Departure or Election of Directors; Appointment of Officers", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1505497/000121390026099018/0001213900-26-099018-index.htm" }, { "form": "8-K", "filed": "2026-09-02", "items": [ "3.03 Material Modifications to Rights of Security Holders", "5.03 Amendments to Articles or Bylaws; Change in Fiscal Year", "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1505497/000121390026096810/0001213900-26-096810-index.htm" }, { "form": "8-K", "filed": "2026-09-02", "items": [ "4.01 Changes in Registrant's Certifying Accountant", "5.02 Departure or Election of Directors; Appointment of Officers", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1505497/000121390026096337/0001213900-26-096337-index.htm" }, { "form": "8-K", "filed": "2026-08-25", "items": [ "3.01 Notice of Delisting or Failure to Satisfy a Listing Rule", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1505497/000121390026093566/0001213900-26-093566-index.htm" }, { "form": "8-K", "filed": "2026-08-14", "items": [ "8.01 Other Events", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1505497/000149315226038391/0001493152-26-038391-index.htm" }, { "form": "8-K", "filed": "2026-07-16", "items": [ "5.02 Departure or Election of Directors; Appointment of Officers", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1505497/000149315226033593/0001493152-26-033593-index.htm" } ], "events12m": 15, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001505497.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1505497" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets, no buy or sell views.", "edgar": "🫧 Edgar looked up BIORESTORATIVE THERAPIES, INC. ($BRTX). Last filing: 8-K (5.02 Departure or Election of Directors; Appointment of Officers), 2026-09-11. 15 event filings (8-K) in the past twelve months. Auditor change (8-K Item 4.01) filed 2026-09-10.", "auditor": { "changes": [ { "filed": "2026-09-10", "url": "https://www.sec.gov/Archives/edgar/data/1505497/000121390026098820/0001213900-26-098820-index.htm" }, { "filed": "2026-09-02", "url": "https://www.sec.gov/Archives/edgar/data/1505497/000121390026096337/0001213900-26-096337-index.htm" }, { "filed": "2025-04-21", "url": "https://www.sec.gov/Archives/edgar/data/1505497/000102177125000074/0001021771-25-000074-index.htm" } ], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2025-12-31", "revenue": 359700, "revenueGrowth1y": -0.10299251870324189, "revenueGrowthPerYear": 0.6722286179735146, "yearsOfData": 5, "operatingMargin": -43.500505977203225, "operatingMarginPrior": -28.815945137157108, "netMargin": -39.59403669724771, "operatingCashFlow": -10788963, "capitalSpending": 116069, "freeCashFlow": -10905032, "researchAndDevelopment": 10094671, "researchShareOfRevenue": 28.064139560745065, "cash": 1511188, "longTermDebt": null, "longTermDebtChange": null, "revenueHistory": [ { "fiscalYearEnd": "2021-12-31", "revenue": 46000 }, { "fiscalYearEnd": "2022-12-31", "revenue": 119800 }, { "fiscalYearEnd": "2023-12-31", "revenue": 145800 }, { "fiscalYearEnd": "2024-12-31", "revenue": 401000 }, { "fiscalYearEnd": "2025-12-31", "revenue": 359700 } ], "totalEquity": 356744, "totalAssets": 4079635, "equityRatio": 0.0874450778072058, "returnOnEquity": -39.92211501805216, "dividendsPaid": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "range80": { "low": 308815.97071195405, "high": 554513.8114241901, "baseline": 420787.5333314539, "n": 749, "band": "b00" }, "ifPaceHeld": { "low": 308815.97071195405, "high": 554513.8114241901 } }, "edgarette": "🔖 Exposure: revenue $360K (FY2025). Experience: revenue down 10.3% on the year, up 67.2% a year over 4 years; operating margin -4350.1%, down from -2881.6%. Soundness: equity 8.7% of assets, return on equity -3992.2%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $309K and $555K next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A range, not a forecast. Against peers (54 filers, $50M+ revenue, its industry group): operating margin -4350.1% against a 2.0% median; growth -10.3% against 13.0%.", "peers": { "sic": 8090, "sicDescription": "Services-Misc Health & Allied Services, NEC", "calendarYear": 2025, "minRevenue": 50000000, "depth": 2, "group": "80", "growth": [ 0.1303, 61 ], "opMargin": [ 0.0199, 54 ], "equityRatio": [ 0.4419, 59 ], "returnOnEquity": [ 0.0155, 49 ], "payoutRatio": [ 0.1928, 13 ] }, "summary": "Biorestorative Therapies (BRTX) saw revenue fall 10.3% in FY2025 to $0 million, operating margin -4350% against a 2.0% median for services-misc health & allied services, nec, equity 8.7% of assets. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
BIORESTORATIVE THERAPIES, INC. against its own record and its peers
Operating marginPeer median 2.0%-4350.1%Revenue, on the yearPeer median 13.0%-10.3%Equity of assetsPeer median 44.2%8.7%Return on equityPeer median 1.6%-3992.2%Gold tick: the median of 49–59 peers with $50M+ revenue in services-misc health & allied services, nec
", "chartHorizon": null, "backtest": { "tests": 10, "hits": 3, "rate": 0.3, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "registry": { "logged": "2026-09-20T14:14:01.884Z", "hash": "cc8f55d542f2d382", "status": "open" }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "Biorestorative Therapies (BRTX) saw revenue fall 10.3% in FY2025 to $0 million, operating margin -4350% against a 2.0% median for services-misc health & allied services, nec, equity 8.7% of assets. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2025-12-31", "revenue": 359700, "totalDebt": null, "cash": 1511188 }, "experience": { "revenueGrowth1y": -0.10299251870324189, "revenueGrowthPerYear": 0.6722286179735146, "operatingMargin": -43.500505977203225, "operatingMarginPrior": -28.815945137157108, "netMargin": -39.59403669724771, "freeCashFlow": -10905032 }, "soundness": { "equityRatio": 0.0874450778072058, "returnOnEquity": -39.92211501805216, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 8090, "sicDescription": "Services-Misc Health & Allied Services, NEC", "calendarYear": 2025, "minRevenue": 50000000, "depth": 2, "group": "80", "growth": [ 0.1303, 61 ], "opMargin": [ 0.0199, 54 ], "equityRatio": [ 0.4419, 59 ], "returnOnEquity": [ 0.0155, 49 ], "payoutRatio": [ 0.1928, 13 ] }, "credibility": { "auditedYears": 5, "weight": "reasonable", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": { "filed": "2026-09-10", "url": "https://www.sec.gov/Archives/edgar/data/1505497/000121390026098820/0001213900-26-098820-index.htm" } }, "range": { "low": 308815.97071195405, "high": 554513.8114241901, "baseline": 420787.5333314539, "coverage": 0.8, "method": "v3", "basis": "next fiscal year revenue: baseline = revenue x (1 + mean of one-year and three-year pace); range = 10th to 90th percentile of how SEC company-years of the same size band actually turned out", "calibratedOn": { "companyYears": 749, "sizeBand": "b00" }, "kind": "a calibrated range, not a forecast; no view on the share price", "track": { "backtest": { "tests": 10, "hits": 3, "rate": 0.3, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "registry": { "logged": "2026-09-20T14:14:01.884Z", "hash": "cc8f55d542f2d382", "status": "open" }, "scorecard": "https://www.pops4.com/boards/scorecard" } }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001505497.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1505497" } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same if-the-pace-held arithmetic applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so." } }